Chardan Capital Issues Pessimistic Forecast for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN - Free Report) had its price objective decreased by Chardan Capital from $55.00 to $35.00 in a research report sent to investors on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

SLN has been the subject of a number of other research reports. The Goldman Sachs Group reduced their price target on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, March 7th. BMO Capital Markets dropped their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 4th. Finally, Morgan Stanley decreased their price target on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $33.83.

Silence Therapeutics Trading Up 3.5%

NASDAQ SLN traded up $0.13 during mid-day trading on Friday, reaching $3.83. 162,205 shares of the company's stock traded hands, compared to its average volume of 298,114. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $24.38. The company has a fifty day simple moving average of $3.37 and a 200-day simple moving average of $6.31. The company has a market cap of $114.63 million, a price-to-earnings ratio of -2.44 and a beta of 1.20.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. Equities research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

A number of hedge funds have recently modified their holdings of the company. Barclays PLC raised its holdings in shares of Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after buying an additional 2,793 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Silence Therapeutics in the 4th quarter worth $26,000. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock worth $42,000 after acquiring an additional 5,233 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after acquiring an additional 6,098 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Silence Therapeutics during the fourth quarter worth about $69,000. Institutional investors own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.